Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation
Status:
Completed
Trial end date:
2011-05-25
Target enrollment:
Participant gender:
Summary
The trial seeks to determine if apixaban, an investigational anticoagulant (blood-thinner) is
as effective as standard therapy (warfarin) in preventing stroke and systemic embolism in
subjects with atrial fibrillation and risk factors for stroke.